Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q3 2024 Infusion Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q3 2024 Infusion Services Update

The infusion therapy market continues to undergo significant expansion pushed by various drivers and a notable transition toward the outpatient setting. Hospitals currently comprise 55% of the estimated $120B infusion service market, but that percentage is expected to diminish in the years to come as primarily the ambulatory and home infusion settings gain market share. To stem the losses, there’s a growing trend of hospital joint ventures with private infusion care providers, allowing the hospital retain a portion of this revenue and infusion providers to selective gain access to 340B drug pricing.

Investors are capitalizing on sector tailwinds including an aging population, an increase in chronic diseases including cancer and diabetes, and a growing pipeline of infusible therapies in line for FDA approval.

Transaction activity in Q3-24 remained strong with several notable transactions closing, including platform developments, strategic add-ons, and a private equity exit.

To print and download the full Infusion Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/10/Q3-2024-Infusion-Services-Newsletter_vP.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]